MDGED
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple so… Read more
MDGED (MDGED) - Total Liabilities
Latest total liabilities as of June 2024: $9.15 Million USD
Based on the latest financial reports, MDGED (MDGED) has total liabilities worth $9.15 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MDGED - Total Liabilities Trend (2020–2023)
This chart illustrates how MDGED's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MDGED Competitors by Total Liabilities
The table below lists competitors of MDGED ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WHARF (HLDGS)
MU:WHA
|
Germany | €56.67 Billion |
|
PIQUADRO
BE:4LZ
|
Germany | €115.23 Million |
|
ECOMMERCE ALLIANCE
BE:ECF
|
Germany | €6.79 Million |
|
HISENSE KELON -H-
MU:GKE
|
Germany | €50.24 Billion |
|
Innerscope Advertising Agency Inc
PINK:INND
|
USA | $14.43 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down MDGED's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MDGED's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MDGED (2020–2023)
The table below shows the annual total liabilities of MDGED from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $10.65 Million | -27.32% |
| 2022-12-31 | $14.65 Million | -0.02% |
| 2021-12-31 | $14.65 Million | -32.15% |
| 2020-12-31 | $21.60 Million | -- |